{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:35:17Z","timestamp":1790116517380,"version":"4.0.1"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Astra Zeneca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The use of systemic glucocorticoids (SGCs) is traditionally discouraged in the treatment of PsA and psoriasis due to the risk of psoriatic flares. However, despite this recommendation, SGCs are frequently prescribed for these patients. In this study we reappraise the old paradigm that SGCs are contra-indicated in the treatment of PsA and psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of MEDLINE, EMBASE and the Cochrane Library databases was performed in November 2019 to identify articles on any SGC use compared with no use in the PsA and psoriasis population. Topical glucocorticoid treatment was excluded. Our two primary outcomes focused on the prescribing characteristics and the occurrence of any type of flare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our search yielded 4922 articles, and of these 21 full-text articles were eligible for inclusion. There were 11 retro- and prospective cohorts involving a total of 4,171,307 patients. Of these, 6727 (37.82%) of the patients with PsA and 1\u200a460\u200a793 (35.17%) of the patients with psoriasis were treated with any type of SGC. Ten observational\/interventional studies did not report an increased risk or occurrence of psoriatic flares related to SGC use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results indicate that SGCs are frequently prescribed for PsA and psoriasis patients. The occurrence of psoriatic flares appears to be low upon SGC exposure. In patients with a clear indication for SGCs, e.g. in need of rapid anti-inflammatory therapy or bridging of therapies, the use of SGCs should be considered in view of the low risk of skin flaring. It remains of importance to weigh risks for short- and long-term SGC-related side effects in clinical decision making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac129","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T15:10:54Z","timestamp":1647011454000},"page":"4232-4244","source":"Crossref","is-referenced-by-count":47,"title":["Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2892-4814","authenticated-orcid":false,"given":"Nanette L A","family":"Vincken","sequence":"first","affiliation":[{"name":"Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht , Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak M W","family":"Balak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, LangeLand Ziekenhuis , Zoetermeer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 C","family":"Knulst","sequence":"additional","affiliation":[{"name":"Department of Dermatology & Allergology, University Medical Centre Utrecht , Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paco M J","family":"Welsing","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht , Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5544-5785","authenticated-orcid":false,"given":"Jacob M","family":"van Laar","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht , Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"2022110208002718900_keac129-B1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"2022110208002718900_keac129-B2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheum"},{"key":"2022110208002718900_keac129-B3","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2022110208002718900_keac129-B4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022110208002718900_keac129-B5","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.berh.2019.03.001","article-title":"Opportunities and challenges in the treatment of psoriatic arthritis","volume":"32","author":"FitzGerald","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2022110208002718900_keac129-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022110208002718900_keac129-B7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/0300060515593260","article-title":"Combination therapy with etanercept in psoriasis: retrospective analysis of efficacy and safety outcomes from real-life practice","volume":"44","author":"Babino","year":"2016","journal-title":"J Int Med Res"},{"key":"2022110208002718900_keac129-B8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/09546630701487643","article-title":"Methotrexate-betamethasone weekly oral pulse in psoriasis","volume":"18","author":"Gupta","year":"2007","journal-title":"J Dermatolog Treat"},{"key":"2022110208002718900_keac129-B9","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022110208002718900_keac129-B10","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2022110208002718900_keac129-B11","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jaad.2020.09.001","article-title":"National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: version 1","volume":"83","author":"Gelfand","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2022110208002718900_keac129-B12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022110208002718900_keac129-B13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2133.1969.tb15995.x","article-title":"Systemic corticosteroids and folic acid antagonists in the treatment of generalized pustular psoriasis. Evaluation and prognosis based on the study of 104 cases","volume":"81","author":"Ryan","year":"1969","journal-title":"Br J Dermatol"},{"key":"2022110208002718900_keac129-B14","first-page":"833","article-title":"Systemic treatment with corticosteroids in psoriasis\u2014health care provision far beyond the S3-guidelines","volume":"9","author":"Augustin","year":"2011","journal-title":"J Dtsch Dermatol Gesell"},{"key":"2022110208002718900_keac129-B15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2310\/7750.2013.13126","article-title":"Systemic corticosteroids are frequently prescribed for psoriasis","volume":"18","author":"Al-Dabagh","year":"2014","journal-title":"J Cutan Med Surg"},{"key":"2022110208002718900_keac129-B16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40261-017-0508-1","article-title":"Initiation, switching, and cessation of psoriasis treatments among patients with moderate to severe psoriasis in the United States","volume":"37","author":"Armstrong","year":"2017","journal-title":"Clin Drug Investig"},{"key":"2022110208002718900_keac129-B17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1468-3083.2012.04656.x","article-title":"Systemic steroids in the treatment of psoriasis: what is fact, what is fiction?","volume":"27","author":"Mrowietz","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2022110208002718900_keac129-B18","first-page":"1","article-title":"Celiac disease","volume":"104","author":"Rostom","year":"2004","journal-title":"Evid Rep Technol Assess (Summ)"},{"key":"2022110208002718900_keac129-B19","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/1346-8138.13862","article-title":"High rate of systemic corticosteroid prescription among outpatient visits for psoriasis: a population-based epidemiological study using the Korean National Health Insurance database","volume":"44","author":"Eun","year":"2017","journal-title":"J Dermatol"},{"key":"2022110208002718900_keac129-B20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s41927-018-0034-7","article-title":"Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry","volume":"2","author":"Kavanaugh","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2022110208002718900_keac129-B21","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/imj.14046","article-title":"Comorbidity in psoriatic arthritis and rheumatoid arthritis","volume":"48","author":"Sinnathurai","year":"2018","journal-title":"Int Med J"},{"key":"2022110208002718900_keac129-B22","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/03007995.2018.1474090","article-title":"Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population","volume":"34","author":"Rice","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"2022110208002718900_keac129-B23","first-page":"1918","article-title":"Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway","volume":"32","author":"Madland","year":"2005","journal-title":"J Rheumatol"},{"key":"2022110208002718900_keac129-B24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/0394632015593220","article-title":"Safety and efficacy of intra-articular anti-tumor necrosis factor \u03b1 agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare","volume":"29","author":"Carubbi","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2022110208002718900_keac129-B25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/jamadermatol.2020.4219","article-title":"Psoriasis flares following systemic glucocorticoid exposure in patients with a history of psoriasis","volume":"157","author":"Gregoire","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2022110208002718900_keac129-B26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/bjd.14061","article-title":"Psoriasis flare with corticosteroid use in psoriatic arthritis","volume":"174","author":"Coates","year":"2016","journal-title":"Br J Dermatol"},{"key":"2022110208002718900_keac129-B27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1358\/mf.2007.29.2.1075348","article-title":"A prospective study of adverse drug reactions in a dermatology department","volume":"29","author":"Ganeva","year":"2007","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"2022110208002718900_keac129-B28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/milmed\/131.7.619","article-title":"Parenteral triamcinolone in the systemic treatment of psoriasis","volume":"131","author":"Brody","year":"1966","journal-title":"Mil Med"},{"key":"2022110208002718900_keac129-B29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/jid.1960.44","article-title":"Triamcinolone and methyl prednisolone in psoriasis. Comparison of their intralesional and systemic effects","volume":"34","author":"Cohen","year":"1960","journal-title":"J Invest Dermatol"},{"key":"2022110208002718900_keac129-B30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13075-018-1565-4","article-title":"Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study","volume":"20","author":"Haroon","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2022110208002718900_keac129-B31","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/rheumatology\/kem030","article-title":"Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study","volume":"46","author":"Saviola","year":"2007","journal-title":"Rheumatology"},{"key":"2022110208002718900_keac129-B32","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3109\/08860220903180582","article-title":"Membranoproliferative glomerulonephritis associated with psoriasis vulgaris","volume":"31","author":"Akoglu","year":"2009","journal-title":"Ren Fail"},{"key":"2022110208002718900_keac129-B33","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1097\/MJT.0b013e31826fc4d1","article-title":"Tumor necrosis factor inhibitor-induced serositis","volume":"21","author":"Annapureddy","year":"2014","journal-title":"Am J Ther"},{"key":"2022110208002718900_keac129-B34","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.4081\/dr.2016.6599","article-title":"Erythrodermic psoriasis treated with apremilast","volume":"8","author":"Arcilla","year":"2016","journal-title":"Dermatol Rep"},{"key":"2022110208002718900_keac129-B35","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1111\/ijd.12755","article-title":"A case of rupioid psoriasis exacerbated by systemic glucocorticosteroids","volume":"54","author":"Bonciani","year":"2015","journal-title":"Int J Dermatol"},{"key":"2022110208002718900_keac129-B36","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1365-2133.2009.09348.x","article-title":"Generalized pustular psoriasis induced by systemic glucocorticosteroids: four cases and recommendations for treatment","volume":"161","author":"Brenner","year":"2009","journal-title":"Br J Dermatol"},{"key":"2022110208002718900_keac129-B37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3810\/pgm.1999.12.813","article-title":"A corticosteroid-induced flare of psoriasis: how to control or, better yet, avoid","volume":"106","author":"Brodell","year":"1999","journal-title":"Postgraduate Med"},{"key":"2022110208002718900_keac129-B38","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2230.2005.01869.x","article-title":"Pustular psoriasis of pregnancy treated with ciclosporin and high-dose prednisolone","volume":"30","author":"Edmonds","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"2022110208002718900_keac129-B39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2230.2005.01910.x","article-title":"Precipitation of generalized pustular psoriasis by prednisolone","volume":"31","author":"Elston","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"2022110208002718900_keac129-B40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/1753495X15626623","article-title":"Two case reports of generalized pustular psoriasis of pregnancy: different outcomes","volume":"9","author":"Flynn","year":"2016","journal-title":"Obstetr Med"},{"key":"2022110208002718900_keac129-B41","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/ddg.13505","article-title":"Psoriasis vulgaris in a patient with pemphigus vulgaris on corticosteroid therapy","volume":"16","author":"Fujimoto","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"2022110208002718900_keac129-B42","doi-asserted-by":"crossref","first-page":"638","DOI":"10.4103\/0378-6323.57743","article-title":"Generalized pustular psoriasis of pregnancy successfully treated with cyclosporine","volume":"75","author":"Hazarika","year":"2009","journal-title":"Ind J Dermatol Venereol Leprol"},{"key":"2022110208002718900_keac129-B43","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4103\/0019-5154.110847","article-title":"Early treatment with addition of low dose prednisolone to methotrexate improves therapeutic outcome in severe psoriatic arthritis","volume":"58","author":"Mahajan","year":"2013","journal-title":"Indian J Dermatol"},{"key":"2022110208002718900_keac129-B44","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1590\/abd1806-4841.20163804","article-title":"Generalized pustular psoriasis induced by systemic steroid dose reduction","volume":"91","author":"Westphal","year":"2016","journal-title":"Anais Brasileiros de Dermatologia"},{"key":"2022110208002718900_keac129-B45","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0190-9622(89)70287-5","article-title":"Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients","volume":"21","author":"Boyd","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"2022110208002718900_keac129-B46","first-page":"113","article-title":"Erythrodermic psoriasis secondary to systemic corticosteroids","volume":"33","author":"Heinrich","year":"2020","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"2022110208002718900_keac129-B47","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/ijd.12070","article-title":"Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: ANALYSIS of 102 cases seen in a tertiary hospital in Johor, Malaysia","volume":"53","author":"Choon","year":"2014","journal-title":"Int J Dermatol"},{"key":"2022110208002718900_keac129-B48","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1590\/S0365-05962010000500005","article-title":"Inter-rater concordance study of the PASI (Psoriasis Area and Severity Index)","volume":"85","author":"Faria","year":"2010","journal-title":"An Bras Dermatol"},{"key":"2022110208002718900_keac129-B49","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/ajd.12280","article-title":"Inter-observer reliability of the PASI in a clinical setting","volume":"56","author":"Cabrera","year":"2015","journal-title":"Australas J Dermatol"},{"key":"2022110208002718900_keac129-B50","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures","volume":"84","author":"Elmets","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2022110208002718900_keac129-B51","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","article-title":"A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis","volume":"71","author":"Ash","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022110208002718900_keac129-B52","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5606\/ArchRheumatol.2018.6946","article-title":"Management of psoriatic arthritis: Turkish League Against Rheumatism (TLAR) expert opinions","volume":"33","author":"Nas","year":"2018","journal-title":"Arch Rheumatol"},{"key":"2022110208002718900_keac129-B53","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1590\/abd1806-4841.20153113","article-title":"Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding","volume":"90","author":"Kurizky","year":"2015","journal-title":"An Bras Dermatol"},{"key":"2022110208002718900_keac129-B54","first-page":"ii74","article-title":"Psoriatic arthritis therapy: NSAIDs and traditional DMARDs","volume":"64(Suppl 2","author":"Nash","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2022110208002718900_keac129-B55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-020-0371-y","article-title":"Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases","volume":"16","author":"Hardy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2022110208002718900_keac129-B56","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrrheum.2010.179","article-title":"Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis","volume":"6","author":"Hoes","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"2022110208002718900_keac129-B57","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar4686","article-title":"The value of glucocorticoid co-therapy in different rheumatic diseases\u2014positive and adverse effects","volume":"16(Suppl 2","author":"van der Goes","year":"2014","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac129\/45030464\/keac129.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/11\/4232\/46747721\/keac129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/11\/4232\/46747721\/keac129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T14:02:45Z","timestamp":1700316165000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/11\/4232\/6548158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":57,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,3,14]]},"published-print":{"date-parts":[[2022,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac129","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,3,14]]}}}